Clinical Trials Browser

NCT06522360 2025-04-24

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03623776 2024-12-06

NAJSCR

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05364645 2024-07-09

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06093503 2024-06-26

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Phase 3 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02531854 2023-12-19

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05948462 2023-12-13

NSCLC

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT04989283 2023-09-26

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05791097 2023-07-24

AdvanTIG-306

Phase 3 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02607423 2023-05-25

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04754815 2022-03-29

HFHS 21-01

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03770299 2022-03-24

CheckMate 9TN

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02662634 2022-03-18

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04061590 2022-03-04

Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04470674 2022-03-03

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04262869 2021-10-27

Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04430933 2021-08-18

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04611776 2021-06-16

CATHAYA

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04203511 2020-06-09

INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)

Phase 3 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03920839 2020-04-24

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Phase 1 Withdrawn

Other solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT03498222 2020-02-25

iTRAP

Phase 1 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02947113 2017-11-30

HYPOLAN

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01928160 2015-07-13

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01336543 2014-12-18

Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01836341 2013-12-19

Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation

Phase 1 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01674738 2013-10-11

SELECT-A

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung